Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Imetelstat

All Publications

Durable Continuous Transfusion Independence With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Platzbecker, et. al.

Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Madanat, et. al.

Relationship Between Durable Transfusion Independence and Survival Outcomes in Patients With Lower-Risk Myelodysplastic Syndrome: An Analysis From US Health Insurance Claims Data

Imetelstat

Komrokji, et. al.

Clinical Pharmacology of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

Imetelstat

Lennox, et. al.

Novel Nonlinear Population Pharmacokinetic Model of Imetelstat, a First-in-Class Oligonucleotide Telomerase Inhibitor

Imetelstat

González Sales, et. al.

Patient-Reported Outcomes Among Heavily Pretreated Patients With Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated With Imetelstat in IMerge

Clinical Imetelstat: MDS Imetelstat

Winter Heme 2024

Sekeres, et. al.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence Across Different Risk Subgroups in Patients With Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents in IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Komrokji, et. al.

Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated With Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database

Imetelstat Relevant MDS Publications

Komrokji, et. al.

Impact of Mutational Status on Clinical Response to Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study

Clinical Imetelstat: MDS Imetelstat

Santini, et. al.

Durable Continuous Transfusion Independence (TI) With Imetelstat in IMerge Phase 3 for Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents

Clinical Imetelstat: MDS Imetelstat

Platzbecker, et. al.